Retatrutide
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented 24.2% weight loss in clinical trials. Expected FDA approval in 2027.
Also referenced as: LY3437943
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when CP-3R crosses your target, drops, or sets a new tracked low—without daily noise.
This compound has a genuine development or study trail, but it is not an approved routine drug.
This profile is grouped by its dominant research area, not by vendor shelf placement.
LY3437943
No FDA label signal · 35 trials · 180 PubMed results
Retatrutide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Retatrutide has 33 name-matched clinical trials (highest phase: Phase 3) and 180 PubMed-indexed publications and is not FDA-approved. 2 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Retatrutide?
Retatrutide is Eli Lilly’s next-generation obesity drug — a triple agonist that simultaneously targets three receptors: GLP-1, GIP, and glucagon. While semaglutide (Ozempic/Wegovy) hits one receptor and tirzepatide (Mounjaro/Zepbound) hits two, retatrutide hits all three. The result? Record-setting weight loss in clinical trials.
How It Works
The triple agonism provides three distinct mechanisms:
- GLP-1 receptor: Suppresses appetite, slows gastric emptying, improves insulin sensitivity
- GIP receptor: Enhances insulin secretion, may improve fat metabolism
- Glucagon receptor: Increases energy expenditure, promotes fat oxidation, lowers fasting glucose
The glucagon component is the key differentiator. While GLP-1 and GIP primarily reduce calorie intake, glucagon actively increases calorie burning — essentially attacking obesity from both sides.
Clinical Trial Results
Phase 2 data showed 24.2% average body weight loss at the highest dose (12mg) over 48 weeks. To put that in perspective:
- Semaglutide (Wegovy): ~15% weight loss
- Tirzepatide (Zepbound): ~22.5% weight loss
- Retatrutide: ~24.2% weight loss
The TRIUMPH Phase 3 program has enrolled 3,000+ participants across multiple trials.
Current Status
Retatrutide is not yet FDA approved. Eli Lilly has targeted an NDA filing in late 2026, with an expected FDA decision in 2027. Currently, access is limited to compounding pharmacies at a cost of approximately $200-500/month.
Side Effects
The side effect profile is similar to other GLP-1 agonists but slightly more pronounced:
- Nausea (most common, usually subsides with dose titration)
- Diarrhea
- Decreased appetite
- Vomiting
- Slightly elevated heart rate (due to glucagon component)
The Bottom Line
Retatrutide represents the cutting edge of obesity pharmacology. If the Phase 3 data holds up, it will likely become the most effective FDA-approved weight loss drug on the market. For those willing to access it through compounding ahead of approval, the cost savings are significant — but you’re accepting more risk with less long-term safety data.